ArticleFrontiers in psychiatry2020
Antidepressant Use in Medicaid-Insured Youth: Trends, Covariates, and Future Research Needs.
Article in Frontiers in psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Precipitants and clinical features of serotonin syndrome: a systematic review with patient-level analysis of published case reports and series.European journal of clinical pharmacology · 2026Pooled it
- Trajectories of antidepressant dispensing among privately insured transgender people in the United States.Scientific reports · 2026Article
- Psychotropic dispensing in Greek adolescents and young adults: national trends and regional variation.Frontiers in drug safety and regulation · 2026Article
- Fluoxetine Use for Very Young Children with Major Depression Disorder: A Pilot Randomized Clinical Trial.Advanced biomedical research · 2026Article
- Exploring the Causal Relationship Between Antidepressant Use and Lung Cancer Risk: A Mendelian Randomization Analysis.The clinical respiratory journal · 2025Article
- Selective serotonin reuptake inhibitors and suicidality in children and young adults: analyses of pharmacovigilance databases.BMC pharmacology & toxicology · 2023Article
- Prescribed psychotropic medication patterns among treated Foster Care enrollees: a single institution study.Frontiers in psychiatry · 2023Article
- The Use of Antidepressants, Antipsychotics, and Stimulants in Youth Residential Care.Journal of child and adolescent psychopharmacology · 2021Article
- Psychotropic Polypharmacy in the US Pediatric Population: A Methodologic Critique and Commentary.Frontiers in psychiatry · 2021Review
- Inter-class Concomitant Pharmacotherapy in Medicaid-Insured Youth Receiving Psychiatric Residential Treatment.Frontiers in psychiatry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDetailed research on long-term antidepressant (AD) trends within a single large US Medicaid population of youth has not heretofore been reported.
methodsAdministrative claims data for eight annual timepoints across 28 years (1987-2014) were organized for youth (<20 years old) who were continuously enrolled during each study year in a mid-Atlantic state Medicaid program. Total annual AD prevalence and age-, gender-, race-, eligibility group-, and diagnosis-specific prevalence were formed from bivariate analyses; logistic regression assessed the change in use (2007-2014) adjusted for covariates. AD-polypharmacy data were assessed in 2014.
resultsThe major findings are: 1) AD use in state Medicaid enrollees grew 14-fold between 1987 and 2014. Data from 2014 revealed significantly increased odds of youth with SSRI/SNRI dispensings compared to 2007 (AOR=1.15 95% CI 1.11-1.19), representing 78% of total AD users. 2) Recent AD increases were greatest for 15-19-year olds. 3) AD use in girls passed up AD use in boys for the first time in 2014. 4) In 2014, ADs for foster care (12.7%) were 6 times greater than for their income-eligible Medicaid-counterparts. 5) In 2014, a quarter of AD-medicated youth were diagnosed with a behavior disorder. 6) More than 40 percent of AD medicated youth had >=1 other concomitant psychotropic classes for 60 or more days.
conclusionsSecond-generation antidepressant use in Medicaid-insured youth has increased despite growing questions that pediatric AD benefits may not outweigh harms. These patterns support the call for publicly funded, independent investigator-conducted post-marketing outcomes research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.